With Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.